Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of Pianzaihuang for preparing medicine capable of treating rheumatoid arthritis

A rheumatoid, Pien Tze Huang technology, applied in the field of medicine, can solve problems such as adverse drug reactions, MTX hypersensitivity, etc., and achieve the effect of good clinical application foundation and good safety.

Inactive Publication Date: 2020-01-03
ZHANGZHOU PIEN TZE HUANG PHARM
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Methotrexate (MTX) is the drug of choice for the treatment of RA, but it usually takes 6 weeks to take effect, and there are obvious individual differences in the sensitivity and tolerance of different patients to MTX. Some patients are highly sensitive to MTX. Sub-low doses may also induce serious adverse drug reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Pianzaihuang for preparing medicine capable of treating rheumatoid arthritis
  • Application of Pianzaihuang for preparing medicine capable of treating rheumatoid arthritis
  • Application of Pianzaihuang for preparing medicine capable of treating rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1 Drug efficacy test of Pien Tze Huang in treating rheumatoid arthritis

[0023] 1. Animal modeling and administration:

[0024] Healthy DBA / 1J mice, male, SPF grade, 6-8 weeks old, for modeling: On day 0 (primary immunization), inject bovine type Ⅱ collagen and complete Freund's adjuvant emulsified intradermally at the base of the tail of the mice On the 21st day (boosting immunization), 100 μL / mouse of emulsifier consisting of bovine type II collagen and incomplete Freund's adjuvant was injected at the same site. The emulsifier used was bovine type II collagen with a concentration of 2 mg / mL was added dropwise to an equal volume of complete or incomplete Freund's adjuvant, and was emulsified with a homogenizer while dripping, with a rotation of 3 min and a stop of 1 min until the The emulsifier does not spread when it is dropped into the water, and the whole process is carried out in an ice bath (the emulsifier is ready for use).

[0025] Grouping and admini...

Embodiment 2

[0049] Example 2 Toxicity study

[0050] Acute toxicity test (single administration): intragastric administration of Pien Tze Huang (12g / kg, 400 times the clinically intended dose) to SD rats for 3 times within 24 hours, and observe the toxicity produced within a certain period of time The results showed that: the rats in the test group had no obvious abnormal symptoms before and after three administrations; there was no abnormality in the general observation of the first 1-14 days after that, and no rats died at the end of the test; no pathological anatomy was observed with the naked eye. Obvious lesions and abnormalities, compared with the vehicle group, there was no statistical difference in body weight.

[0051] 180-day toxicity test: set up 270mg / kg, 900mg / kg, 3000mg / kg dose groups and vehicle control group, observe the toxic reaction and dose-response relationship of rats, whether there is delayed toxic reaction after drug withdrawal and the reversibility of toxic reacti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of Pianzaihuang for preparing a medicine capable of treating rheumatoid arthritis. A collagen induced arthritis mouse model is adopted to prove that the Pianzaihuang can obviously improve a CIA (collagen induced arthritis) mouse arthritis index, improve a mouse ankle joint pathological index and obviously lower mouse serum inflammatory factor expression. The treatment effect of the Pianzaihuang is equivalent to the treatment effect of a positive medicine-methotrexate, and in addition, safety is good so as to point out that the Pianzaihuang has a clinic valuethat the Pianzaihuang can be applied to the treatment of the rheumatoid arthritis.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of Pien Tze Huang in the preparation of medicines for treating rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disease that occurs in synovial joints and other organ systems. The main feature is that the lesion can involve the large and small joints of the whole body. The clinical manifestations of RA are mainly morning stiffness, joint swelling and pain, cartilage destruction and narrowing of the joint space. If left untreated, it can lead to joint disability and a decrease in quality of life, shortening life expectancy by 3 to 10 years, and bringing a huge economic burden to society . [0003] The pathogenesis of rheumatoid arthritis has not yet been fully clarified, and the etiology of the pathogenesis is complex. During the pathogenesis, some cell subsets are aggregate...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/258A61P29/00A61P19/02A61K35/413A61K35/55A61K35/583
CPCA61K35/413A61K35/55A61K35/583A61K36/258A61P19/02A61P29/00A61K2300/00
Inventor 王世聪陈志亮于娟洪绯简凯丽庄毅超殷婷婷林丽敏
Owner ZHANGZHOU PIEN TZE HUANG PHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com